Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in th

327 patient records from a two-centre cohort study show a 19.8% incidence of acute hypoxemic respiratory failure (AHRF) following neoadjuvant immunochemotherapy for thoracic tumours. The data, collected from December 2017 to June 2023, was analyzed using propensity score matching and multivariable logistic regressions. Author Shenglan Tan published the study on figshare under a CC-BY-4.0 license.

Use Cases

• Assessing the association between neoadjuvant immunochemotherapy and postoperative AHRF risk based on patient cohort data.
• Identifying high-risk subgroups for AHRF based on factors like cancer type (NSCLC, SCC) and treatment response (non-pCR).
• Evaluating the impact of the time interval between neoadjuvant therapy and surgery on complication rates.
• Validating statistical models for postoperative risk prediction using propensity score matching methods.

Strengths

• Includes 327 patient records from a two-centre study, providing a multi-source cohort.
• Covers a specific time range from December 2017 to June 2023.
• Analysis employs established statistical methods like propensity score matching and multivariable logistic regression.
• Results include specific odds ratios (e.g., OR = 2.41) and confidence intervals for risk assessment.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small at 883.9 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Retrospective cohort study using clinical records.

Time Range

December 2017 to June 2023

Freshness

Last updated 2026-05-18 09:20:03; freshness should be verified.